BioPorto 2020 HC Andersen Capital Nordea Small Cap Seminar

BioPorto presented its NGAL test solution for acute kidney injury at the HC Andersen Capital/Nordea Small Cap Seminar. The presentation covers the company's novel diagnostic platform, addressable market opportunity, regulatory strategy, and development pipeline including the gRAD platform.